SwePub
Sök i LIBRIS databas

  Utökad sökning

hsv:(MEDICAL AND HEALTH SCIENCES) hsv:(Clinical Medicine) hsv:(Hematology)
 

Sökning: hsv:(MEDICAL AND HEALTH SCIENCES) hsv:(Clinical Medicine) hsv:(Hematology) > Different Procoagul...

Different Procoagulant Activity of Therapeutic Mesenchymal Stromal Cells Derived from Bone Marrow and Placental Decidua

Moll, Guido (författare)
Karolinska Institutet,Charite, Nephrol & Intens Care Med, D-13353 Berlin, Germany.;Berlin Brandenburg Sch Regenerat Therapies BSRT, Berlin, Germany.;Karolinska Inst, Lab Med, Stockholm, Sweden.
Ignatowicz, Lech (författare)
Lund University,Lunds universitet,Dermatologi och venereologi, Lund,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Dermatology and Venereology (Lund),Section III,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund Univ, Dept Clin Sci, Lund, Sweden.
Catar, Rusan (författare)
Charite, Dept Nephrol & Intens Care Med, D-13353 Berlin, Germany.
visa fler...
Luecht, Christian (författare)
Charite, Dept Nephrol & Intens Care Med, D-13353 Berlin, Germany.
Sadeghi, Behnam (författare)
Karolinska Institutet,Karolinska Inst, Lab Med, Stockholm, Sweden.
Hamad, Osama (författare)
Uppsala universitet,Institutionen för immunologi, genetik och patologi
Jungebluth, Philipp (författare)
Karolinska Inst, Dept Clin Sci Intervent & Technol CLINTEC, Adv Ctr Translat Regenerat Med ACTREM, Stockholm, Sweden.;Heidelberg Univ, Dept Thorac Surg, Thoraxklin, Heidelberg, Germany.
Dragun, Duska (författare)
Charite, Berlin Brandenburg Sch Regenerat Therapies BSRT, D-13353 Berlin, Germany.;Charite, Dept Nephrol & Intens Care Med, D-13353 Berlin, Germany.
Schmidtchen, Artur (författare)
Lund University,Lunds universitet,Dermatologi och venereologi, Lund,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Dermatology and Venereology (Lund),Section III,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund Univ, Dept Clin Sci, Lund, Sweden.
Ringden, Olle (författare)
Karolinska Institutet,Karolinska Inst, Lab Med, Stockholm, Sweden.
visa färre...
Karolinska Institutet Charite, Nephrol & Intens Care Med, D-13353 Berlin, Germany;Berlin Brandenburg Sch Regenerat Therapies BSRT, Berlin, Germany.;Karolinska Inst, Lab Med, Stockholm, Sweden. (creator_code:org_t)
Mary Ann Liebert Inc, 2015
2015
Engelska.
Ingår i: Stem Cells and Development. - : Mary Ann Liebert Inc. - 1547-3287 .- 1557-8534. ; 28:S2, s. 50-51
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • While therapeutic mesenchymal stromal/stem cells (MSCs) have usually been obtained from bone marrow, perinatal tissues have emerged as promising new sources of cells for stromal cell therapy. In this study, we present a first safety follow-up on our clinical experience with placenta-derived decidual stromal cells (DSCs), used as supportive immunomodulatory and regenerative therapy for patients with severe complications after allogeneic hematopoietic stem cell transplantation (HSCT). We found that DSCs are smaller, almost half the volume of MSCs, which may favor microvascular passage. DSCs also show different hemocompatibility, with increased triggering of the clotting cascade after exposure to human blood and plasma in vitro. After infusion of DSCs in HSCT patients, we observed a weak activation of the fibrinolytic system, but the other blood activation markers remained stable, excluding major adverse events. Expression profiling identified differential levels of key factors implicated in regulation of hemostasis, such as a lack of prostacyclin synthase and increased tissue factor expression in DSCs, suggesting that these cells have intrinsic blood-activating properties. The stronger triggering of the clotting cascade by DSCs could be antagonized by optimizing the cell graft reconstitution before infusion, for example, by use of low-dose heparin anticoagulant in the cell infusion buffer. We conclude that DSCs are smaller and have stronger hemostatic properties than MSCs, thus triggering stronger activation of the clotting system, which can be antagonized by optimizing the cell graft preparation before infusion. Our results highlight the importance of hemocompatibility safety testing for every novel cell therapy product before clinical use, when applied using systemic delivery.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Hematologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Hematology (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Medicinsk bioteknologi -- Medicinsk bioteknologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Medical Biotechnology -- Medical Biotechnology (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Annan klinisk medicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Other Clinical Medicine (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kirurgi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Surgery (hsv//eng)

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy